z-logo
open-access-imgOpen Access
Immune Checkpoints: Therapeutic Targets for Pituitary Tumors
Author(s) -
Ding Nie,
Yimeng Xue,
Qiuyue Fang,
Jianhua Cheng,
Bin Li,
Dawei Wang,
Chuzhong Li,
Songbai Gui,
Yazhuo Zhang,
Peng Zhao
Publication year - 2021
Publication title -
disease markers
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.912
H-Index - 66
eISSN - 1875-8630
pISSN - 0278-0240
DOI - 10.1155/2021/5300381
Subject(s) - immune system , immunotherapy , pituitary tumors , cancer research , immunity , immunology , immune checkpoint , biology , medicine
Pituitary tumors are the third most common intracranial tumors in adults. Treatment of refractory pituitary tumors is known to be difficult due to limited treatment options. As a promising therapeutic method, tumor immunotherapy has been applied in the treatment of many tumors, including pituitary tumors. Immune checkpoint blocking is one of the effective strategies to activate antitumor immunity. Immune checkpoints prevent tissue damage by regulating the immune response of peripheral tissues and participate in the maintenance of a normal immune environment. In the presence of a tumor, inhibition of T cell activity by tumor cells binding to immune checkpoints and their ligands is an important mechanism for tumor cells to escape immune injury. In this review, we summarize the latest findings of immune checkpoints and their potential as immunotherapeutic targets for pituitary tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom